| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Mucosal Resection | 30 | 2025 | 77 | 12.520 |
Why?
|
| Colonoscopy | 15 | 2025 | 249 | 4.420 |
Why?
|
| Adenoma | 7 | 2025 | 146 | 3.520 |
Why?
|
| Colonic Polyps | 9 | 2025 | 83 | 3.320 |
Why?
|
| Colorectal Neoplasms | 12 | 2025 | 630 | 3.080 |
Why?
|
| Esophageal Neoplasms | 10 | 2024 | 386 | 2.960 |
Why?
|
| Stomach Neoplasms | 11 | 2024 | 565 | 2.670 |
Why?
|
| Exocrine Pancreatic Insufficiency | 4 | 2024 | 34 | 2.630 |
Why?
|
| Colonic Neoplasms | 5 | 2025 | 263 | 2.570 |
Why?
|
| Adenocarcinoma | 11 | 2024 | 1018 | 2.460 |
Why?
|
| Pancreatic Neoplasms | 11 | 2025 | 728 | 2.200 |
Why?
|
| Pancreatitis, Chronic | 6 | 2024 | 76 | 2.170 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 8 | 2024 | 81 | 2.160 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2024 | 87 | 1.690 |
Why?
|
| Suture Techniques | 2 | 2025 | 189 | 1.510 |
Why?
|
| Barrett Esophagus | 5 | 2024 | 355 | 1.500 |
Why?
|
| Pancreatitis | 5 | 2021 | 140 | 1.500 |
Why?
|
| Pancreatic Cyst | 4 | 2021 | 28 | 1.490 |
Why?
|
| Gastrectomy | 5 | 2020 | 102 | 1.430 |
Why?
|
| Flavonoids | 2 | 2022 | 86 | 1.380 |
Why?
|
| Endoscopy, Gastrointestinal | 8 | 2024 | 240 | 1.330 |
Why?
|
| Early Detection of Cancer | 7 | 2025 | 414 | 1.330 |
Why?
|
| Myotomy | 7 | 2025 | 21 | 1.300 |
Why?
|
| Treatment Outcome | 33 | 2025 | 13027 | 1.240 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 4 | 2025 | 32 | 1.240 |
Why?
|
| Gastric Mucosa | 5 | 2024 | 491 | 1.210 |
Why?
|
| Humans | 108 | 2025 | 132238 | 1.150 |
Why?
|
| Operative Time | 4 | 2025 | 192 | 1.130 |
Why?
|
| Esophagoscopy | 6 | 2025 | 168 | 1.100 |
Why?
|
| Middle Aged | 41 | 2025 | 29021 | 1.070 |
Why?
|
| Aged | 33 | 2025 | 21482 | 1.030 |
Why?
|
| Endoscopy, Digestive System | 5 | 2024 | 157 | 0.990 |
Why?
|
| Retrospective Studies | 32 | 2025 | 17395 | 0.990 |
Why?
|
| Duodenoscopy | 1 | 2025 | 17 | 0.950 |
Why?
|
| Duodenal Neoplasms | 1 | 2025 | 26 | 0.940 |
Why?
|
| Wound Closure Techniques | 1 | 2025 | 27 | 0.920 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 58 | 0.890 |
Why?
|
| Male | 54 | 2025 | 65013 | 0.880 |
Why?
|
| MicroRNAs | 4 | 2024 | 916 | 0.860 |
Why?
|
| Postoperative Complications | 8 | 2025 | 3139 | 0.860 |
Why?
|
| Antioxidants | 4 | 2024 | 333 | 0.840 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 134 | 0.830 |
Why?
|
| Fundoplication | 1 | 2024 | 70 | 0.830 |
Why?
|
| Natural Orifice Endoscopic Surgery | 5 | 2025 | 72 | 0.820 |
Why?
|
| Plant Extracts | 2 | 2022 | 135 | 0.820 |
Why?
|
| Female | 52 | 2025 | 70780 | 0.820 |
Why?
|
| Colonic Diseases | 1 | 2023 | 38 | 0.810 |
Why?
|
| Endosonography | 7 | 2025 | 82 | 0.810 |
Why?
|
| Trastuzumab | 1 | 2024 | 154 | 0.810 |
Why?
|
| Colon | 2 | 2022 | 370 | 0.760 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 278 | 0.760 |
Why?
|
| Sutures | 2 | 2022 | 69 | 0.750 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 96 | 0.750 |
Why?
|
| Prospective Studies | 17 | 2025 | 6568 | 0.740 |
Why?
|
| Ocimum basilicum | 1 | 2021 | 1 | 0.740 |
Why?
|
| Berberine | 1 | 2021 | 10 | 0.730 |
Why?
|
| Selenium | 1 | 2021 | 15 | 0.730 |
Why?
|
| Gastroesophageal Reflux | 2 | 2024 | 338 | 0.710 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 387 | 0.710 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2021 | 1304 | 0.700 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 21 | 0.700 |
Why?
|
| Esophagectomy | 1 | 2021 | 67 | 0.690 |
Why?
|
| Hypoglycemic Agents | 2 | 2022 | 482 | 0.680 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2011 | 119 | 0.670 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 898 | 0.670 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 145 | 0.670 |
Why?
|
| Crohn Disease | 1 | 2023 | 290 | 0.660 |
Why?
|
| Biopsy, Needle | 1 | 2021 | 234 | 0.660 |
Why?
|
| Intestinal Mucosa | 5 | 2023 | 796 | 0.650 |
Why?
|
| Receptor, ErbB-2 | 1 | 2024 | 549 | 0.650 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 7138 | 0.640 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2021 | 23 | 0.640 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2022 | 305 | 0.640 |
Why?
|
| Endoscopy | 3 | 2023 | 288 | 0.640 |
Why?
|
| Liver | 4 | 2022 | 1797 | 0.640 |
Why?
|
| Catheter Ablation | 1 | 2022 | 257 | 0.630 |
Why?
|
| Esophageal Achalasia | 3 | 2025 | 46 | 0.630 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 114 | 0.620 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 122 | 0.620 |
Why?
|
| Gastric Stump | 1 | 2019 | 1 | 0.620 |
Why?
|
| Esophageal Motility Disorders | 3 | 2025 | 22 | 0.610 |
Why?
|
| Indomethacin | 1 | 2019 | 82 | 0.600 |
Why?
|
| Stents | 4 | 2023 | 874 | 0.600 |
Why?
|
| Pancreatic Diseases | 3 | 2023 | 39 | 0.580 |
Why?
|
| Helicobacter pylori | 3 | 2023 | 1336 | 0.580 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 236 | 0.580 |
Why?
|
| Nanoparticles | 1 | 2021 | 288 | 0.580 |
Why?
|
| Cholangitis | 2 | 2016 | 40 | 0.580 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 297 | 0.580 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3092 | 0.580 |
Why?
|
| Helicobacter Infections | 3 | 2023 | 1278 | 0.580 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 12 | 0.570 |
Why?
|
| Malabsorption Syndromes | 1 | 2018 | 29 | 0.560 |
Why?
|
| Pancreas | 6 | 2023 | 222 | 0.550 |
Why?
|
| Biopsy | 3 | 2024 | 1288 | 0.540 |
Why?
|
| Quality of Life | 4 | 2024 | 2161 | 0.530 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 1365 | 0.520 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 64 | 0.520 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 36 | 0.520 |
Why?
|
| Needles | 1 | 2017 | 53 | 0.520 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 132 | 0.520 |
Why?
|
| Sensitivity and Specificity | 6 | 2024 | 2139 | 0.510 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 1829 | 0.510 |
Why?
|
| Adult | 20 | 2025 | 31614 | 0.500 |
Why?
|
| Intestinal Polyps | 2 | 2024 | 29 | 0.500 |
Why?
|
| Breast Neoplasms | 3 | 2025 | 2676 | 0.490 |
Why?
|
| Oxidative Stress | 5 | 2025 | 801 | 0.490 |
Why?
|
| Feces | 2 | 2018 | 753 | 0.490 |
Why?
|
| Dissection | 3 | 2021 | 59 | 0.490 |
Why?
|
| Lymphatic Metastasis | 4 | 2020 | 444 | 0.480 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1683 | 0.480 |
Why?
|
| Pyloric Antrum | 1 | 2015 | 62 | 0.480 |
Why?
|
| Common Bile Duct | 1 | 2015 | 15 | 0.470 |
Why?
|
| Radiography, Abdominal | 1 | 2015 | 49 | 0.470 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 40 | 0.460 |
Why?
|
| Silver | 2 | 2025 | 29 | 0.450 |
Why?
|
| Kidney | 1 | 2021 | 1338 | 0.440 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 13 | 0.440 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 94 | 0.440 |
Why?
|
| Gastroparesis | 1 | 2015 | 67 | 0.440 |
Why?
|
| Metal Nanoparticles | 2 | 2025 | 56 | 0.440 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2023 | 1249 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1307 | 0.420 |
Why?
|
| Quality of Health Care | 1 | 2017 | 424 | 0.410 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 325 | 0.410 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 168 | 0.400 |
Why?
|
| Obesity | 1 | 2025 | 2398 | 0.400 |
Why?
|
| Metaplasia | 3 | 2022 | 217 | 0.390 |
Why?
|
| Margins of Excision | 2 | 2024 | 57 | 0.390 |
Why?
|
| Cholagogues and Choleretics | 1 | 2012 | 26 | 0.390 |
Why?
|
| Fluid Therapy | 2 | 2019 | 147 | 0.390 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2012 | 38 | 0.390 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2012 | 5 | 0.390 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 23 | 0.380 |
Why?
|
| Colic | 1 | 2012 | 10 | 0.380 |
Why?
|
| Gallstones | 1 | 2012 | 20 | 0.380 |
Why?
|
| Streptozocin | 2 | 2022 | 26 | 0.370 |
Why?
|
| Apoptosis | 4 | 2025 | 1899 | 0.370 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2012 | 73 | 0.360 |
Why?
|
| Carcinoma, Ehrlich Tumor | 2 | 2024 | 3 | 0.360 |
Why?
|
| Pilot Projects | 4 | 2024 | 1444 | 0.360 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1418 | 0.350 |
Why?
|
| Mediastinum | 1 | 2011 | 48 | 0.350 |
Why?
|
| Bacteremia | 1 | 2015 | 428 | 0.340 |
Why?
|
| Financing, Government | 1 | 2011 | 32 | 0.340 |
Why?
|
| Feasibility Studies | 4 | 2024 | 821 | 0.340 |
Why?
|
| Research Support as Topic | 1 | 2011 | 62 | 0.340 |
Why?
|
| Birth Weight | 1 | 2012 | 351 | 0.330 |
Why?
|
| Rats | 5 | 2023 | 3604 | 0.320 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 208 | 0.300 |
Why?
|
| Colonoscopes | 1 | 2009 | 10 | 0.300 |
Why?
|
| Tumor Burden | 3 | 2017 | 248 | 0.280 |
Why?
|
| Surgical Instruments | 2 | 2025 | 57 | 0.280 |
Why?
|
| Models, Statistical | 2 | 2025 | 495 | 0.280 |
Why?
|
| Microscopy, Confocal | 2 | 2019 | 364 | 0.280 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2023 | 88 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 664 | 0.280 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2018 | 55 | 0.270 |
Why?
|
| Risk Factors | 7 | 2024 | 10944 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 333 | 0.270 |
Why?
|
| Blood Glucose | 2 | 2022 | 1121 | 0.270 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 551 | 0.270 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 420 | 0.260 |
Why?
|
| Paclitaxel | 2 | 2024 | 140 | 0.240 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3414 | 0.240 |
Why?
|
| Biostatistics | 1 | 2025 | 14 | 0.230 |
Why?
|
| Cystadenoma, Serous | 1 | 2025 | 7 | 0.230 |
Why?
|
| Risk Assessment | 4 | 2024 | 3736 | 0.230 |
Why?
|
| Caffeine | 1 | 2025 | 64 | 0.230 |
Why?
|
| Biomedical Research | 1 | 2011 | 554 | 0.220 |
Why?
|
| Duodenum | 1 | 2025 | 113 | 0.220 |
Why?
|
| Electrosurgery | 1 | 2024 | 17 | 0.220 |
Why?
|
| Gels | 1 | 2024 | 72 | 0.210 |
Why?
|
| Esophageal Stenosis | 1 | 2024 | 46 | 0.210 |
Why?
|
| Pancreatic Ducts | 2 | 2022 | 22 | 0.210 |
Why?
|
| Salvage Therapy | 1 | 2025 | 200 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 76 | 0.200 |
Why?
|
| Recurrence | 2 | 2021 | 1453 | 0.200 |
Why?
|
| Glycosides | 1 | 2023 | 9 | 0.200 |
Why?
|
| Aftercare | 1 | 2024 | 155 | 0.200 |
Why?
|
| Diet, High-Fat | 2 | 2022 | 255 | 0.200 |
Why?
|
| Calculi | 1 | 2022 | 16 | 0.190 |
Why?
|
| Lithotripsy | 1 | 2022 | 30 | 0.190 |
Why?
|
| Propensity Score | 1 | 2024 | 255 | 0.190 |
Why?
|
| Rectum | 1 | 2023 | 114 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2025 | 576 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 127 | 0.190 |
Why?
|
| Animals | 9 | 2025 | 34845 | 0.190 |
Why?
|
| Postoperative Care | 1 | 2024 | 312 | 0.190 |
Why?
|
| Niacin | 1 | 2022 | 59 | 0.190 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 237 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 233 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3761 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2552 | 0.180 |
Why?
|
| Endothelin-1 | 1 | 2021 | 43 | 0.180 |
Why?
|
| Cyst Fluid | 1 | 2021 | 6 | 0.180 |
Why?
|
| Gastroscopy | 1 | 2022 | 102 | 0.180 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2021 | 5 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 5410 | 0.180 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 387 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1541 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 282 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1127 | 0.170 |
Why?
|
| United States | 6 | 2025 | 11669 | 0.170 |
Why?
|
| Time Factors | 4 | 2020 | 6451 | 0.170 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 259 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2022 | 161 | 0.170 |
Why?
|
| Japan | 2 | 2018 | 156 | 0.170 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 124 | 0.170 |
Why?
|
| Chronic Pain | 1 | 2022 | 148 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 241 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 350 | 0.160 |
Why?
|
| Equipment Design | 2 | 2024 | 600 | 0.160 |
Why?
|
| Bile Ducts | 1 | 2019 | 54 | 0.150 |
Why?
|
| Proteome | 1 | 2021 | 278 | 0.150 |
Why?
|
| Endoscopes | 1 | 2019 | 19 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 317 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 816 | 0.150 |
Why?
|
| Fatigue | 1 | 2020 | 201 | 0.150 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 240 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2025 | 1700 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 232 | 0.150 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 304 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 382 | 0.140 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2018 | 15 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 166 | 0.140 |
Why?
|
| Triglycerides | 1 | 2021 | 617 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2018 | 151 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2024 | 1122 | 0.140 |
Why?
|
| Cecum | 1 | 2017 | 28 | 0.140 |
Why?
|
| Ulcer | 1 | 2017 | 50 | 0.140 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 76 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1348 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 149 | 0.130 |
Why?
|
| Biomarkers | 3 | 2021 | 3404 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 1966 | 0.130 |
Why?
|
| Adolescent | 6 | 2021 | 20556 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 305 | 0.130 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 57 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 302 | 0.130 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 174 | 0.130 |
Why?
|
| Insulin | 1 | 2021 | 1168 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2021 | 698 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 2062 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2314 | 0.120 |
Why?
|
| Jaundice | 1 | 2016 | 27 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1294 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 257 | 0.120 |
Why?
|
| Cisplatin | 1 | 2016 | 282 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2022 | 739 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 226 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 725 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 743 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2018 | 389 | 0.110 |
Why?
|
| Prognosis | 1 | 2024 | 5016 | 0.110 |
Why?
|
| Gastroenterology | 1 | 2017 | 211 | 0.110 |
Why?
|
| Esophageal Sphincter, Lower | 2 | 2024 | 13 | 0.110 |
Why?
|
| Survival Rate | 1 | 2019 | 2196 | 0.100 |
Why?
|
| Texas | 3 | 2017 | 3632 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 3018 | 0.100 |
Why?
|
| Young Adult | 3 | 2018 | 9966 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2016 | 314 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1718 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 700 | 0.100 |
Why?
|
| Mice | 4 | 2025 | 18502 | 0.100 |
Why?
|
| Cholecystectomy | 1 | 2012 | 64 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2023 | 517 | 0.090 |
Why?
|
| Inflammation | 3 | 2025 | 1522 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 1255 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2024 | 240 | 0.080 |
Why?
|
| Hospitalization | 2 | 2025 | 1902 | 0.080 |
Why?
|
| Enterotoxins | 1 | 1990 | 82 | 0.080 |
Why?
|
| Mass Screening | 1 | 2015 | 830 | 0.080 |
Why?
|
| Mercury Poisoning | 1 | 2009 | 4 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2510 | 0.080 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2009 | 79 | 0.080 |
Why?
|
| Bacterial Toxins | 1 | 1990 | 176 | 0.070 |
Why?
|
| Inhalation Exposure | 1 | 2009 | 35 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 156 | 0.070 |
Why?
|
| Linear Models | 1 | 2011 | 714 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2012 | 417 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2021 | 14736 | 0.070 |
Why?
|
| Retinitis Pigmentosa | 1 | 2009 | 96 | 0.070 |
Why?
|
| Music Therapy | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2008 | 43 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2009 | 232 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 416 | 0.070 |
Why?
|
| Diarrhea | 1 | 1990 | 331 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2008 | 71 | 0.070 |
Why?
|
| Bacteroides Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| Spondylitis | 1 | 2007 | 8 | 0.070 |
Why?
|
| Bacteroides fragilis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Escherichia coli Proteins | 1 | 1990 | 316 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2024 | 60 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 128 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2008 | 93 | 0.070 |
Why?
|
| Colitis | 1 | 2009 | 164 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2012 | 523 | 0.060 |
Why?
|
| Warfarin | 1 | 2008 | 128 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1500 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 113 | 0.060 |
Why?
|
| Infant | 3 | 2018 | 13049 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 272 | 0.060 |
Why?
|
| Esophageal Spasm, Diffuse | 1 | 2025 | 3 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2025 | 51 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8548 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2024 | 93 | 0.050 |
Why?
|
| Escherichia coli | 1 | 1990 | 995 | 0.050 |
Why?
|
| Child | 4 | 2021 | 25783 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 95 | 0.050 |
Why?
|
| North America | 1 | 2024 | 265 | 0.050 |
Why?
|
| Pancreatic Hormones | 1 | 2023 | 5 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2023 | 47 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 49 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2008 | 609 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Disaccharides | 1 | 2022 | 21 | 0.050 |
Why?
|
| Vinca Alkaloids | 1 | 2022 | 2 | 0.050 |
Why?
|
| Hydrolyzable Tannins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 312 | 0.050 |
Why?
|
| Acetylcholinesterase | 1 | 2022 | 23 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2022 | 61 | 0.050 |
Why?
|
| Vitamin E | 1 | 2022 | 63 | 0.050 |
Why?
|
| Manganese | 1 | 2022 | 58 | 0.050 |
Why?
|
| Neuroprotection | 1 | 2022 | 31 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2025 | 516 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 152 | 0.050 |
Why?
|
| Saudi Arabia | 1 | 2021 | 41 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 312 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 89 | 0.040 |
Why?
|
| Vinblastine | 1 | 2021 | 57 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2024 | 470 | 0.040 |
Why?
|
| Bleomycin | 1 | 2021 | 113 | 0.040 |
Why?
|
| Fibrosis | 1 | 2023 | 421 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2021 | 98 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 658 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2022 | 333 | 0.040 |
Why?
|
| Models, Animal | 1 | 2023 | 469 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2022 | 239 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 400 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 67 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2020 | 34 | 0.040 |
Why?
|
| Manometry | 1 | 2020 | 72 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 286 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 213 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 844 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 303 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 337 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 334 | 0.040 |
Why?
|
| Bile | 1 | 2019 | 46 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 262 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 462 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7557 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 689 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2022 | 1224 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 67 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 720 | 0.040 |
Why?
|
| Optical Fibers | 1 | 2019 | 19 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 377 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2019 | 49 | 0.040 |
Why?
|
| Lasers | 1 | 2019 | 117 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 666 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 471 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 511 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 47 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 2232 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 106 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 127 | 0.040 |
Why?
|
| Smoking | 1 | 2023 | 940 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2023 | 4718 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3689 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2022 | 5176 | 0.030 |
Why?
|
| Esophagus | 1 | 2019 | 234 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
|
| Resuscitation | 1 | 2019 | 270 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 234 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2016 | 217 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 210 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2008 | 368 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 437 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3995 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 607 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1671 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4687 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3376 | 0.020 |
Why?
|
| Malaysia | 1 | 1990 | 17 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 926 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1990 | 54 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 34 | 0.020 |
Why?
|
| Dark Adaptation | 1 | 2009 | 36 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 1990 | 89 | 0.020 |
Why?
|
| Electroretinography | 1 | 2009 | 121 | 0.020 |
Why?
|
| Refractive Errors | 1 | 2009 | 65 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2923 | 0.020 |
Why?
|
| Visual Fields | 1 | 2009 | 145 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 626 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2008 | 60 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 81 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 703 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 806 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 159 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 352 | 0.020 |
Why?
|
| Metronidazole | 1 | 2007 | 156 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2009 | 707 | 0.010 |
Why?
|
| Cross Infection | 1 | 2008 | 343 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2008 | 1653 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 482 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 270 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1382 | 0.010 |
Why?
|